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Background/Aims. One of the causes of uncontrolled secondary hyperparathyroidism (sHPT) is patient’s poor drug adherence.
We evaluated the clinical benefits of an integrated care approach on the control of sHPT by cinacalcet. Methods. Prospective,
randomized, controlled, multicenter, open-label study. Fifty hemodialysis patients on a stable dose of cinacalcet were randomized
to an integrated care approach (IC) or usual care approach (UC). In the IC group, cinacalcet adherence was monitored using an
electronic system. Results were discussed with the patients in motivational interviews, and drug prescription adapted accordingly.
In the UC group, drug adherence was monitored, but results were not available. Results. At six months, 84% of patients in the
IC group achieved recommended iPTH targets versus 55% in the UC group (𝑃 = 0.04). The mean cinacalcet taking adherence
improved by 10.8% in the IC group and declined by 5.3% in the UC group (𝑃 = 0.02). Concomitantly, the mean dose of cinacalcet
was reduced by 7.2mg/day in the IC group and increased by 6.4mg/day in the UC group (𝑃 = 0.03). Conclusions.The use of a drug
adherencemonitoring program in themanagement of sHPT in hemodialysis patients receiving cinacalcet improves drug adherence
and iPTH control and allows a reduction in the dose of cinacalcet.
1. Introduction
Poor adherence is an important problem in the dialysis pop-
ulation, where patients should not only adhere to medication
intake but also to strict dialysis hours and complicated dietary
recommendations [1]. Depending on the definition used for
adherence (previously called compliance), between 50% and
85% of dialysis patients may be considered nonadherent [2].
Low adherence to drugs used in the treatment of renal bone
disorders is particularly worrisome, since high levels of intact
parathyroid hormone (iPTH), elevated phosphorus (PO
4
),
and Ca × PO
4
product have been associated with increased
morbidity and mortality rates [3–6]. Although the lack of
effectiveness of drug therapy may also play a role, adherence
is an important issue since the average patient takes six to ten
pills per day to control their calcium phosphate product [7],
and numerous studies have demonstrated that adherence is
inversely related to the number of pills taken daily [8].
The calcimimetic cinacalcet is an effective drug for
the treatment of secondary hyperparathyroidism (sHPT) in
dialysis patients [9, 10]. It is actually unclear whether a lack
of response to a therapeutic dose of cinacalcet is the result of
resistance to the drug or of poor adherence. Distinguishing
these possibilities is clinically relevant, because increasing the
dose in a nonadherent patient will only increase the costs
of the treatment, without improving the clinical results. In
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Figure 1: Example of MEMS graphical report (once a day prescription). Note: points correspond to an MEMS-box opening, and grey bars
correspond to days without opening.
this respect, in a retrospective cohort study including 4923
patients in the USA, greater cinacalcet adherence was associ-
ated with inpatient cost savings of $4000–$8900/patient/year
[11].
An effective way to monitor adherence to medica-
tion intake is the “Medication Events Monitoring System”
(MEMS). This electronic monitoring system records each
time (date and hour) the pillbox containing the drug under
investigation is opened. Today this is considered as the most
sensitive and valid method tomeasure medication adherence
[12]. We have previously shown in a pilot study [13] that
measuring the adherence to cinacalcet and phosphate binders
allows the detection of nonadherence and thereby improves
the control of sHPT in hemodialysis patients with suspected
nonadherence. However, as the study was uncontrolled, it
remained unclear whether this improvement was simply the
effect of introducing the electronic monitoring system, or
whether it was the result of the discussions of adherence data
which took place between physician, patient, and pharmacist.
The main objective of this prospective randomized con-
trolled study was to assess whether an integrated care (IC)
approach, in which adherence data are integrated in the
decisional process, leads to improved therapeutic control of
sHPT and higher percentages of bone metabolism targets as
compared to a usual care (UC) approach, in which biological
values represent the main stem of the decisional process.
Moreover, we hypothesized that the bone metabolism targets
would be reached at a lower dose of cinacalcet in the IC group
as compared to the UC group.
2. Subjects and Methods
This was a prospective randomized, multicenter open-label
study performed in nine dialysis facilities in Switzerland.
Adult patients on maintenance hemodialysis (MHD) since
more than three months, treated with a daily dose of cinacal-
cet of ≥30mg for at least one month and iPTH values in
or above target according to the treating nephrologists, were
eligible for inclusion. Patients with intolerance to cinacalcet,
previous or plannedparathyroidectomy for suspected tertiary
hyperparathyroidism, or patientswith hypocalcaemia (serum
calcium < 7.48mg/dL (< 1.87mmol/L)) were excluded. Other
exclusion criteria were the inability to understand the pro-
tocol, mental diseases, or a short-life expectancy (less than
six months). The study was carried out under good clinical
practice, according to the principles of the Declaration of
Helsinki. Written informed consent was obtained from each
patient. The study was approved by all regional ethical
committees. The study was registered as ClinicalTrials.gov
(Nr.268/09).
Eligible patients were randomly assigned 1 : 1 to the IC
or UC groups. A central randomization system was used,
assigning participants within centers in blocks of four. After
inclusion, adherence to cinacalcet was monitored using the
MEMS system (MEMS SmartCap, Medication Event Moni-
toring System, Aardex Group, Ltd., Sion, Switzerland) for six
months, followed by an observation period of three months
without monitoring in each group. In the intervention group
(IC group), adherence data were available for therapeutic
decisions, whereas in the UC group adherence data were
blinded until the end of the study. In the IC group, drug
adherence results were discussed with the patients by the
treating nephrologists in semistructured motivational inter-
views at intervals of two months. The first motivational
interviews based on MEMS results took place after two
months in the IC group; theywere repeated every twomonths
thereafter. No adherence data were available in the UC group
throughout the study.
During the interviews, patients were asked to describe
their experience and complications with medication intake.
Drug adherence results were discussed through the help
of the MEMS graphical report, which allowed the direct
visualization of date and hour of the consecutive MEMS-box
openings (see Figure 1). Potential barriers to adherence were
identified, strategies to overcome the barriers were generated
with the patient, and an individualized adherence plan was
elaborated. At each subsequent meeting, the interventionist
evaluated whether the strategies had been implemented and
generated alternative strategies if necessary. Of note, none
of the main authors of this study were involved in drug
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prescription, nor were any of the treating physicians involved
in the statistical analysis of the results of the study.
In the UC group, therapeutic decisions were based on
blood chemistry only. Blood samples for iPTH, phosphorus,
and total calcium were obtained at baseline and at two, four,
six, and nine months. Blood analyses were performed in each
local center.
iPTH, phosphorus, and calcium targets, as well as the
prescription of dialysis treatments and additional drugs
were left to the discretion of the treating nephrologists.
Importantly, in both groups physicians were asked to define
their target values of iPTH, phosphorus, and calcium in
their center before starting the protocol. Cinacalcet dose
changes were performed by the treating nephrologists at two-
month intervals between baseline and six months and at
their discretion between six and ninemonths. Cinacalcet was
conditioned in the electronic pillbox every two months by
center collaborators, according to Good Pharmacist Practices
guidelines. Patients were instructed to open the pillbox when
it was time to take cinacalcet, to remove the prescribed dose,
and to close the package directly thereafter.
In the IC group, dosing history data were downloaded
from MEMS and discussed with the treating nephrologist at
the end of each two-month interval. For theUCgroup, dosing
history data were downloaded at the end of each two-month
interval; neither the patient nor the treating nephrologists
had access to the adherence results until the end of the
study (blinding). Before the start of the study, physicians and
patients were asked to predict patient’s adherence status using
a categorical scale from 1 (very poor, ≤50% prescribed doses
taken), 2 (50–80% prescribed doses taken), and 3 (85–95%
prescribed doses taken) to 4 (excellent, ≥95% prescribed dose
taken).
Endpoints of the study were the mean dose of cinacalcet
at six months needed to achieve the iPTH targets values, the
absolute values and changes in iPTH values at six months
from baseline, changes in cinacalcet taking adherence at
six months from baseline, absolute and relative change
in cinacalcet doses at six months from baseline, and the
percentage of patients on iPTH target at six months. The
parameter used to assess adherence was the taking adherence,
defined as the ratio between the number of dose taken and
the number of dose prescribed.
For a complete evaluation of the practice patterns in sHPT
management, the usage of vitamin D sterols (oral calcitriol,
oral and IV paricalcitol) and phosphate binders was assessed
at two-month intervals until the end of the study. Safety
and tolerability were assessed in terms of the incidence of
adverse drug reactions (ADR), serious ADRs, and deaths. An
ADR was defined as an adverse event that the investigator
considered to be attributed to the use of cinacalcet.
Continuous variables were summarized as means (stan-
dard deviation) for normally distributed variables or median
(interquartile range (iqr)) for nonnormally distributed con-
tinuous variables. Chi-square test was used to compare
categorical data. Student’s t-test was used for normally dis-
tributed continuous variables, and Wilcoxon rank-sum test
was used to compare nonnormally distributed continuous
variables between the two groups; Wilcoxon signed-rank
test was used to compare matched pairs of non-normally
distributed continuous variables within groups. A two-sided
𝑃 value< 0.05 was considered to be significant. Analyses were
performed using STATA software version 11.0.
3. Results
The study took place between January 2010 and April 2012.
The study flow diagram is shown in Figure 2.
Out of the 50 patients initially enrolled and included in
the study (𝑛 = 24 in the IC group, 𝑛 = 26 in the UC group),
five patients in the IC group and four in the UC group did
not complete the study period, for several reasons: kidney
transplantation (𝑛 = 2), death (𝑛 = 1), incident neoplastic
disease (𝑛 = 2), cinacalcet-related de novo gastrointestinal
side effects (𝑛 = 1), and violation of the predefined
exclusion criteria of previous or planned parathyroidectomy
for suspected tertiary hyperparathyroidism (𝑛 = 3). Only
patients who completed the six-month study period were
considered in the final analysis.
Baseline characteristics of the UC group (𝑛 = 22) and the
IC group (𝑛 = 19) were comparable with regard to age, sex,
dialysis time, biologic parameters, and prescription of drugs
(Table 1), with the exception of a higher paricalcitol dose in
the IC group at baseline (𝑃 < 0.05).
3.1. Control of sHPT. Themedian (iqr) iPTH value decreased
in the IC group from 417 ng/L (iqr: 352; 622) at baseline
to 339 ng/L (236; 529) after six months (𝑃 = 0.03). In
the UC group, no significant change was observed: median
(iqr) iPTH 419 ng/L (275; 548) at baseline and 436 ng/L (288;
682) at six months (𝑃 = 0.1) (Figure 3(a)). Hence, the
median (iqr) change in iPTH was negative in the IC group:
−94.3 ng/L (−282.6; −27.7) and positive in the UC group:
+113.6 ng/L (−26.2; 145.1) (𝑃 = 0.009) (Figure 3(b)). Of note,
after discontinuation of theMEMSmonitoring (months from
six to nine), median (iqr) iPTH values rose slightly in both
groups: +16.0 ng/L (−163.3; +197.1) in the UC group (𝑃 = 1.0)
and +50.0 ng/L (−85.8; +304.1) in the IC group (𝑃 = 0.2)
(Figure 3(a)). The other biological parameters of phosphorus
and calcium metabolism, namely, serum Ca, PO
4
, and Ca ×
PO
4
product, did not differ between the groups, nor were any
changes observed throughout the study. At 6 months, 84% of
patients in the IC group had iPTH levels within the KDIGO
guidelines, as compared to 55% of the UC group (𝑃 = 0.04).
Only 42% of the IC group and 23% of patients of the UC
group had iPTH levels in the KDOQI range (𝑃 = 0.2). 68% of
patients in the IC group and 50% in the UC group achieved
the predefined nephrologists targets (𝑃 = 0.2).
3.2. Prescription of Cinacalcet. Themean (sd) cinacalcet dose
could be reduced from 42.0 (20.8) to 34.7 (26.5) mg/day
in the IC group, corresponding to a mean (sd) change
of −7.2 (19.8) mg/day (−17%), whereas in the UC group
there was a dose increase from 31.6 (13.4) to 38.0 (24.6)
mg/day, corresponding to a mean (sd) change of +6.4 (19.9)
mg/day (+20%) (𝑃 = 0.03). Hence, the relative difference in
percentage of dose change between the two groups was 37%
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Figure 2: Schematic representation of patients randomization and followup.
Table 1: Baseline clin1ical characteristics of patients who completed the study.
UC group IC group P value
𝑁 22 19
Age (years) 61.3 (9.8) 59.1 (15.6) 0.6
Men (%) 59 79 0.2
BMI (kg/m2) 26.5 (3.5) 26.4 (4.1) 0.7
Previous transplant (%) 33 16 0.4
Time on dialysis (months) 50 (48) 50 (45) 0.6
Dialysis time (hours/week) 11.4 (0.9) 11.7 (0.5) 0.3
Calcium dialysate (mmol/L) 1.59 (0.91) 1.53 (0.84) 0.8
iPTH baseline 419 (275; 548) 417 (352; 622) 0.5
Cinacalcet dose (mg/d) 31.6 (13.4) 42.0 (20.8) 0.1
Cinacalcet taking adherence 93.7 (3.3) 84.4 (5.4) 0.1
PO4-chelators (𝑛) 1.1 (0.6) 1.2 (1.2) 0.7
Active Vit. D3 (calcitriol) (mcg/week) 1 (0.3) 1.3 (0.5) 0.7
Active Vit. D3 (paricalcitol) (mcg/week) 0 6 (3) <0.05
Inactive Vit. D3 (UI/week) 2179 (4078) 1597 (3351) 0.5
Values are expressed as mean (standard deviations) or median (25th; 75th percentile) as appropriate.
(Figure 4). Considering other concomitant treatments, no
difference between groups was noted throughout the study.
3.3. Drug Adherence. During the first two months of MEMS
monitoring, themean (min-max) percentage of taking adher-
ence was 84.4% (29.8–101.8) in the IC group and 93.7% (41.0;
107.7) in the UC group (𝑃 = 0.1). At the end (last two
months of monitoring) of the six-month MEMS monitoring
period, the mean (sd) intake increased by 10.3% (18.6) in the
IC group. In contrast, it decreased by 5.5% (19.8) in the UC
group (𝑃 = 0.02) (Figure 5). We found a good concordance
betweenphysician predicted adherence andmeasured patient
adherence at baseline, when fixing a cutoff at 80%: 87.5% of
patients (7 out of 8) with taking adherence at baseline <80%
and 75.8% (25 out of 33) with taking adherence >80% were
correctly identified by the physician. Only 62.5% (5 out of 8)
patients with taking adherence <80% and 81.8% (27 out of
33) of patients with adherence >80% correctly predicted their
results before start of adherence monitoring.
In subgroups analysis, those patients with lower (≤90%)
taking adherence at baseline benefited most from the IC
approach: their mean (sd) change in taking adherence was
+31.5% in the IC group versus −4.5% in the UC group (𝑃 =
0.04). For patients with taking adherence at baseline >90%,
no difference was observed between the two approaches.
Consistently with the previous observation, patients with
taking adherence at baseline ≤90% showed a significant
biological response to the IC approach, with a median (iqr)
iPTH change at six months from baseline of −101.8 ng/L
(−424; −78.6) versus +114.1 ng/L (−96.0; +614.0) in the UC
group (𝑃 = 0.03).
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Figure 3: Absolute intact parathyroid hormone (iPTH) values (a) and iPTH mean changes (b). Note: conversion factors for units: iPTH in
ng/L to pmol/L, divided by 9.43.
3.4. Tolerability and Safety. Adverse events were reported
in 0.7% of patients, namely, gastrointestinal disturbances
(three cases), necessitating drug suspension in one case.
Hypocalcemia (serum calcium < 7.48mg/dL, < 1.87mmol/L)
was observed in 29 over 369 measures (7.9%), none of which
were symptomatic. Serious AEs occurred in two patients: one
died (sudden cardiac death unrelated to cinacalcet intake);
the second patient was prematurely withdrawn from the
study because of incident neoplastic disease necessitating
hospitalization.
4. Discussion
Taken together, the results of the present study confirm
that an integrated care (IC) approach significantly improves
the control of secondary hyperparathyroidism (sHPT) in
dialysis patients: the IC approach improves the adherence
to cinacalcet, enables to reduce the cinacalcet dose without
changing the prescription of phosphate binders and vita-
min D derivatives, and increases the number of patients
reaching iPTH targets. However, the positive effects of the
intervention were maintained only during the monitoring
and had vanished three months after the interruption of the
drug adherence monitoring, suggesting that the intervention
should be of longer duration.
To the best of our knowledge, this is the first prospective
randomized study in haemodialysis patients that analyzed
the impact of integrating drug adherence data obtained by
electronic pillbox monitoring on the control of sHPT. One
common criticism to the use of electronicmonitoring of drug
adherence in interventional studies is that the introduction
of the device per se enhances drug adherence and hence
improves clinical results. Our controlled study demonstrates
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Figure 4: Change in cinacalcet dose over six-month MEMS moni-
toring.
that simply introducing electronic monitoring, without dis-
closing adherence results to physicians and patients, is not
enough to improve adherence and sHPT control and does
not improve the clinical targets. As such, the existence of an
“adherence increasing effect” due to the use of an electronic
monitoring system alone without feedback to the patients
is not supported by our data. Indeed, only an integrated
care approach, combining the interpretation of the unique
patient’s data by a trained physician and the periodical
feedback to the patient, led to a therapeutic benefit. This
further emphasizes the importance of the quality of the
physician/patient interaction in improving drug adherence.
With the IC approach we actually counteracted and reversed
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Figure 5: Change in individual taking adherence over six-month MEMS monitoring.
the trend of drug adherence to decline over time as observed
in our control group and in previous observational studies
[14, 15]. The high sensitivity of iPTH control to cinacalcet
adherence is not surprising, when considering the well-
established short half-life of cinacalcet and its immediate
effect on iPTH level [16].
One might argue that the changes in iPTH levels, reduc-
tion in cinacalcet dose, and improvement in adherence were
relatively modest. This is most likely due to the fact that the
inclusion of patients was not restricted to those with a low
drug adherence at baseline. Thus, in order to simulate “real-
life practice,” even patients with a good adherence at baseline
were enrolled. Moreover, drug adherence monitoring was
only performed during six months. It is, however, well
recognized that drug adherence decreases progressively with
time in many diseases [14]. In this respect, it is important to
note that patients with estimated baseline taking adherence
below 90% (26.8% of all patients) mostly benefited from the
integrated care approach. These data indicate that, if this
approachwould be introduced in general practice, it is crucial
to carefully select patients for monitoring in order to avoid
excessive expenses and labour forces. In this context, we
propose the use of a step-up approach. Electronicmonitoring
of drug adherence should be considered in all patients with
suspected poor adherence or patients needing very high
doses of cinacalcet to control iPTH. If a low drug adherence
is confirmed by the monitoring or if clinical values improve
significantly during themonitoring, the IC approach could be
proposed in order to sustain drug adherence in the long run.
It is clear that the clinical effectiveness of such an approach
needs to be validated in a prospective study.
The loss of effect after the interruption of the IC
approach is classical and has been observed in previous
studies assessing drug adherence in other pathologies [12].
It indicates a lack of long-term effect of the motivational
teaching. This might be partly related to the short duration
of our intervention (six months). Our findings are also
in line with the statements that adherence is a dynamic
parameter [14] and that continuous efforts are needed to
ascertain adherence over time. Further study is needed to
assess the duration of the IC approach needed to obtain
a definite change in behaviour. Nevertheless, the improve-
ment of clinical parameters during the monitoring provides
important information for physicians, as it indicates what
clinical results can be obtained when the patient is taking
his/her treatment correctly. Thus, when clinical parameters
worsen again, physicians should probably intervene on drug
adherence rather than increase the drug doses.
Two other points deserve attention. First, mean baseline
adherence in our studywas high and superior to the threshold
of 80% that arbitrarily defines good adherence [17]. Consider-
ing the complex drug regimens (six–ten pills/day) imposed to
dialysis patients and the known inverse relationship between
drug adherence and the number of daily tablets to be taken
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[7, 18], we had expected to find lower drug adherence results.
However, adherence results were similar to those observed in
kidney transplant patients on immunosuppressive drugs [18]
and hypercholesterolemic patients treated with atorvastatin
[19]. Once again, the short duration of our study can probably
account for these good results as drug adherence tends to
decrease after six months.
Second, physicians’ ability to recognize patients with poor
adherence was good, with over 80% of patients with taking
adherence <80% being correctly identified before adherence
monitoring started. Conversely, only 62.5% of patients with
poor adherence (<80%) acknowledged adherence problems
before the start of the study. This is in contrast with previous
data from other disciplines [12]. A possible explanation
might be that nephrologists are better able to predict patient
adherence, thanks to the unique relationship with their
patients, consisting (in general) of several patient-physician
contacts per week.
The main limitation of this multicenter study design is
the lack of a central laboratory; all biochemical markers of
the bone metabolism were measured locally. In order to
minimize heterogeneity of iPTH levels, exclusively second-
generation PTH assays measuring the intact 1–84 PTH were
used in all centers, and the same assay was used in the same
patient throughout the study. However, we cannot exclude
residual variance in laboratory parameters.
Contamination between study armsmight have occurred,
due to the fact that the same physician took care of both study
groups. However, physicians were blinded to drug adherence
results of theUC group until study end.They therefore lacked
the most important objective tool to evaluate drug adherence
and elaborate a corrective intervention. Furthermore, an
effort was made to standardize motivational interviews, in
order to homogenize the intervention between study centers.
In conclusion, the use of a drug adherence monitoring-
based interventional approach in hemodialysis patients
receiving cinacalcet for sHPT enabled to unmask and
improve drug adherence problems and to transiently achieve
better iPTH control at a lower dose of cinacalcet. Patients
with poor adherence at baseline mostly benefitted from the
integrated care approach, suggesting that in this patient group
the adherence monitoring-based interventional approach
should be proposed before increasing cinacalcet dose.
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